Jørn Herrstedt1, Yvonne Summers2, Gedske Daugaard3, Thomas B Christensen4, Karin Holmskov5, Paul D Taylor2, Gabriel M Fox6, Alexander Molassiotis7,8. 1. Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark. herrstedt@rsyd.dk. 2. Pulmonary Oncology Unit, University Hospital South Manchester, Manchester, UK. 3. Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 4. Department of Oncology, Herlev Hospital, Copenhagen, Denmark. 5. Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000, Odense C, Denmark. 6. Acacia Pharma, Cambridge, UK. 7. School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK. 8. School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.
Abstract
PURPOSE: The purpose of this study was to investigate the antiemetic effect of the dopamine D2- and dopamine D3-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy. METHODS: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT3-receptor antagonist, ondansetron. The primary parameter was complete response (0-24 h), defined as no emesis and no need for rescue antiemetics. Secondary parameters were number of emetic episodes, severity of nausea and time to first emetic episode and start of nausea. RESULTS: A total of 51 patients were enrolled and evaluable. None of the 10 patients in the 2.5 and 7.5 mg groups obtained a CR. In the 20 mg monotherapy cohort, two of the 18 subjects (11%) had a CR, 3/18 (17%) had no emesis and 12/18 (67%) had no significant nausea. Seven subjects (39%) had no nausea at all (a VAS score < 5 mm). In the combination (ondansetron plus amisulpride) cohort, 19/23 (83%; 90% confidence interval: 65-94%) had a CR and 14/23 (61%) had no nausea at all. CONCLUSIONS: Amisulpride has antiemetic effect against cisplatin-induced acute nausea and vomiting. The effect against nausea is of particular interest. Randomised studies are warranted to further explore the effect and safety of amisulpride.
PURPOSE: The purpose of this study was to investigate the antiemetic effect of the dopamine D2- and dopamine D3-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy. METHODS: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT3-receptor antagonist, ondansetron. The primary parameter was complete response (0-24 h), defined as no emesis and no need for rescue antiemetics. Secondary parameters were number of emetic episodes, severity of nausea and time to first emetic episode and start of nausea. RESULTS: A total of 51 patients were enrolled and evaluable. None of the 10 patients in the 2.5 and 7.5 mg groups obtained a CR. In the 20 mg monotherapy cohort, two of the 18 subjects (11%) had a CR, 3/18 (17%) had no emesis and 12/18 (67%) had no significant nausea. Seven subjects (39%) had no nausea at all (a VAS score < 5 mm). In the combination (ondansetron plus amisulpride) cohort, 19/23 (83%; 90% confidence interval: 65-94%) had a CR and 14/23 (61%) had no nausea at all. CONCLUSIONS:Amisulpride has antiemetic effect against cisplatin-induced acute nausea and vomiting. The effect against nausea is of particular interest. Randomised studies are warranted to further explore the effect and safety of amisulpride.
Authors: Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: P Kranke; L Eberhart; J Motsch; D Chassard; J Wallenborn; P Diemunsch; N Liu; D Keh; H Bouaziz; M Bergis; G Fox; T J Gan Journal: Br J Anaesth Date: 2013-07-19 Impact factor: 9.166
Authors: F Roila; M Tonato; F Cognetti; E Cortesi; G Favalli; M Marangolo; D Amadori; M A Bella; V Gramazio; D Donati Journal: J Clin Oncol Date: 1991-04 Impact factor: 44.544
Authors: P J Hesketh; G Rossi; G Rizzi; M Palmas; A Alyasova; I Bondarenko; A Lisyanskaya; R J Gralla Journal: Ann Oncol Date: 2014-03-07 Impact factor: 32.976
Authors: Jörg Täubel; Georg Ferber; Gabriel Fox; Sara Fernandes; Ulrike Lorch; A John Camm Journal: Br J Clin Pharmacol Date: 2016-10-21 Impact factor: 4.335